Logo

Alnylam Presents 18-Month Results of Vutrisiran in P-III (HELIOS-A) Study for the Treatment of hATTR Amyloidosis with Polyneuropathy

Share this

Alnylam Presents 18-Month Results of Vutrisiran in P-III (HELIOS-A) Study for the Treatment of hATTR Amyloidosis with Polyneuropathy

Shots:

  • The P-III (HELIOS-A) study evaluated the efficacy & safety of vutrisiran (25mg, SC, q3mos.) vs patisiran (0.3 mg/kg, IV, q3w) in a ratio (3:1) in 164 patients with hATTR amyloidosis with polyneuropathy across 57 sites in 22 countries
  • The trial met all 2EPs i.e., improvement in clinical EPs & non-inferiority in serum TTR reduction over patisiran, improvement in mNIS+7 (48% vs 4%), gait speed, nutritional status, QoL (57% vs 10%) & overall disability over PBO
  • The therapy also showed an improvement in exploratory cardiac EPs @18mos., including biomarker NT-proBNP, echocardiographic parameters & cardiac uptake of technetium on scintigraphy imaging along with promising safety profile

Ref: Businesswire | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions